|
Gender
| | |
0.754
| | |
0.346
|
|
· Female
|
24 (85.7)
|
4 (14.3)
| |
10 (34.5)
|
19 (65.5)
| |
|
· Male
|
36 (80.0)
|
9 (20.0)
| |
23 (46.9)
|
26 (53.1)
| |
|
Age
| | |
0.127
| | |
0.653
|
|
· ≤ 68-years old (median)
|
34 (89.5)
|
4 (10.5)
| |
18 (45.0)
|
22 (55.0)
| |
|
· > 68-years old (median)
|
26 (74.3)
|
9 (25.7)
| |
15 (39.5)
|
23 (60.5)
| |
|
CEA (carcinoembryonic antigen)
| | |
1.000
| | |
0.813
|
|
· Within normal range
|
39 (83.0)
|
8 (17.0)
| |
21 (41.2)
|
30 (58.8)
| |
|
· ≥ ULN (5 ng/ml)
|
21 (80.8)
|
5 (19.2)
| |
12 (44.4)
|
15 (55.6)
| |
|
Primary tumour location
| | |
1.000
| | |
0.051
|
|
· Colon
|
47 (82.5)
|
10 (17.5)
| |
22 (36.1)
|
39 (63.9)
| |
|
Rectum
|
13 (81.3)
|
3 (18.8)
| |
11 (64.7)
|
6 (35.3)
| |
|
Tumour histology
| | |
0.401
| | |
0.221
|
|
· Conventional adenocarcinoma
|
52 (83.9)
|
10 (16.1)
| |
30 (45.5)
|
36 (54.5)
| |
|
· Mucinous or colloid adenocarcinoma
|
8 (72.7)
|
3 (27.3)
| |
3 (25.0)
|
9 (75.0)
| |
|
TNM stage
| | |
0.196
| | |
0.170
|
|
· I-II
|
23 (92.0)
|
2 (8.0)
| |
8 (30.8)
|
18 (69.2)
| |
|
· III-IV
|
37 (78.7)
|
10 (21.3)
| |
24 (47.1)
|
27 (52.9)
| |
|
Tumour differentiation
| | |
0.053
| | |
0.586
|
|
· Well differentiated
|
15 (100)
|
0 (0.0)
| |
7 (36.8)
|
12 (63.3)
| |
|
· Moderately or poorly differentiated
|
37 (77.1)
|
11 (22.9)
| |
23 (47.9)
|
25 (52.1)
| |
|
Surgery of primary tumor
| | |
0.578
| | |
0.389
|
|
· Yes
|
55 (80.9)
|
13 (19.1)
| |
32 (43.8)
|
41 (56.2)
| |
|
· No
|
5 (100.0)
|
0 (0.0)
| |
1 (20.0)
|
4 (80.0)
| |
|
Surgery of metastasis
| | |
0.953
| | |
0.451
|
|
· Yes
|
13 (86.7)
|
2 (13.3)
| |
9 (50.0)
|
9 (50.0)
| |
|
· No
|
47 (81.0)
|
11 (19.0)
| |
24 (40.0)
|
24 (40.0)
| |
|
Adjuvant chemotherapy
| | |
0.295
| | |
0.986
|
|
· Yes
|
28 (87.5)
|
4 (12.5)
| |
14 (42.4)
|
19 (57.6)
| |
|
· No
|
32 (78.0)
|
9 (22.0)
| |
19 (42.2)
|
26 (57.8)
| |
|
Chemotherapy for advanced disease
| | |
0.683
| | |
0.929
|
|
· Yes
|
36 (83.7)
|
7 (16.3)
| |
18 (41.9)
|
25 (58.1)
| |
|
· No
|
24 (80.0)
|
6 (20.0)
| |
15 (42.9)
|
20 (57.1)
| |
